AI
About Arrowhead Research
Overview
Arrowhead Research Corporation is a holding company that forms, acquires, and operates portfolio companies commercializing innovative nanotechnologies. By working closely with leading scientists and universities, Arrowhead identifies the latest advances in nanotechnology and matches them with product development opportunities in high-growth markets. The Company is currently focused on the electronics and biotech industries.
Providing strategic management, financing, and operational services to its portfolio companies, Arrowhead takes an active role in their development, keeping the business and technical development teams at the portfolio level focused on near term revenue opportunities and capital efficiency.
Arrowhead’s strategy is to maintain or build a majority ownserhip position in each portfolio company, thus providing significant exposure to their growth. Arrowhead’s ultimate goal is to monetize the value of its subsidiaries through an initial public offering of subsidiary stock or a sale of a subsidiary to another company. Alternatively, Arrowhead could retain ownership of subsidiary to capture its continuing cash flow and income. Arrowhead is currently focused on its two majority-owned subsidiaries, Unidym, Inc. and Calando Pharmaceuticals, Inc. Arrowhead also owns interests in other development stage nanotechnology companies and is seeking to selectively add to its portfolio.
Download Corporate Profile ( PDF )
http://www.arrowheadresearch.com/corporate_profile_about.html
Management Team
Christopher Anzalone, Ph.D.
President and CEO
Dr. Anzalone is the President and Chief Executive Officer of Arrowhead Research and a majority stockholder of Unidym. He has a wealth of experience in nanotechnology, biotechnology, company-building, and venture capital. Prior to joining Arrowhead, Dr. Anzalone founded and built The Benet Group, a private equity firm focused on creating and building new nanobiotechnology companies from university-generated science. Included in The Benet Group's portfolio are investments in two nanotechnology companies: Nanotope Inc., a tissue regeneration company, and Leonardo Biosystems Inc., a cancer drug delivery company. Prior to Benet, Dr. Anzalone was a partner at the Washington DC-based private equity firm Galway Partners, LLC where he was in charge of sourcing, structuring, and building new business ventures. He was also the founding CEO of NanoInk, Inc., a leading nanolithography company.
Dr. Anzalone holds a Ph.D. and M.A. in Biology from UCLA and a B.A. in Government from Lawrence University.
Board of Directors
Christopher Anzalone, PhD. is the company’s CEO. He is also a member of the company’s board of directors.
R. Bruce Stewart is the founder, director, and Executive Chairman of the Board of Arrowhead Research. A life-long entrepreneur, Mr. Stewart has started and funded over eighteen companies and has taken several of them to the public markets. His capital market experience spans thirty years and he has raised substantial capital for both public and private companies. He is known for his success in building value for shareholders and innovating novel strategies in corporate finance.
Edward W. Frykman has been an Account Executive with Crowell, Weedon & Co. since 1992. Previously, Mr. Frykman served as Senior Vice President of L.H. Friend & Co. Both Crowell, Weedon & Co. and L.H. Friend & Co. are investment brokerage firms located in Southern California. In addition, Mr. Frykman was a Senior Account Executive with Shearson Lehman Hutton where he served as the Manager of the Los Angeles Regional Retail Office of E. F. Hutton & Co.
LeRoy (Lee) T. Rahn was a partner with the intellectual property law firm of Christie, Parker & Hale for more than 30 years, whose practice focused on assisting clients in protecting their intellectual property through obtaining, maintaining and enforcing patents and other legal rights. He is a former president of the Los Angeles Intellectual Property Association and frequently makes presentations on intellectual property law to legal and trade groups. Prior to becoming an attorney, Mr. Rahn obtained a degree in electrical engineering.
Charles P. McKenney has maintained a government affairs law practice in Pasadena, California since 1989, representing businesses and organizations in their relations with government regarding their obligations under state and local land use and trade practices laws. From 1973 through 1989, he served as Attorney for Corporate Government Affairs for Sears, Roebuck and Co., helping organize and carry out Sears' Western state and local government relations programs. Mr. McKenney has served two terms on the Pasadena, California City council, on several city boards and committees in Pasadena, including three city Charter Reform Task Forces.
Scientific Advisory Board
Dr. Mauro Ferrari serves as a Professor & Director, Center for NanoMedicine, Brown Foundation Institute of Molecular Medicine, Chairman, Department of Biomedical Engineering, University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Professor of Bioengineering, Rice University, and President of the Alliance for NanoHealth, Houston TX. Dr. Ferrari received a Ph.D. in Mechanical Engineering from U.C. Berkeley. Dr. Ferrari is a founder of biomedical nano/micro-technology in biomedical applications with more than 160 peer-reviewed journal articles, six books, more than 20 issued patents and about thirty more pending in the US and internationally. His career research and development portfolio totals over $50 million. Dr. Ferrari served as Special Expert on Nanotechnology at the National Cancer Institute in 2003-2005, providing leadership into the establishment of the NCI's Alliance for Nanotechnology.
Dr. Lee Hartwell is a well-known expert in cancer biology and was awarded the Nobel Prize in Medicine in 2001 for his ground-breaking work in cell cycle regulation. Dr. Hartwell is President of the Fred Hutchinson Cancer Research Center in Seattle, Washington. His insights into cell cycle control are being used at the Hutchinson Center and elsewhere to develop treatments for cancer and other diseases. Dr. Hartwell is involved in national and international projects to increase the number of laboratories working in protein diagnostics, develop more team science, improve the availability of informatics for data sharing, provide standardized reagents and stimulate new technology development. Dr. Hartwell is the recipient of many national and international scientific awards. His honors include the Albert Lasker Basic Medical Research Award, the Gairdner Foundation International Award and the Alfred P. Sloan Award in cancer research. He is a member of the National Academy of Sciences. He earned his B.S. at the California Institute of Technology and his Ph.D. from the Massachusetts Institute of Technology. He joined the University of Washington faculty in 1968 and has been a genetics professor there since 1973. In 1996, he joined the faculty of Seattle's Fred Hutchinson Cancer Research Center and, in 1997, became its president and director.
Dr. Andrew von Eschenbach served as Commissioner of the U.S. Food and Drug Administration from 2005 until 2009 where he engaged an agenda to modernize the FDA. Under his leadership, many new programs were designed to strengthen the FDA, including the establishment of a nanotechnology initiative. He emphasized the FDA’s role in working with external partners to assure quality throughout the entire life cycle of the products it regulates while internally fostering, through process improvements, a regulatory pathway that is transparent and efficient while still rigorous and science led. Currently, Dr. von Eschenbach serves as Senior Director for Strategic Initiatives at the Center for Health Transformation, founded by Newt Gingrich, and leads the 21st Century FDA Modernization Project. Dr. von Eschenbach joined the FDA after serving for four years as Director of the National Cancer Institute (NCI) at the National Institutes of Health where he set an ambitious goal to eliminate the suffering and death due to cancer by rapid acceleration and integration of the discovery-development-delivery continuum. While at NCI, he committed resources to ensure the application to oncology of nanotechnology, genomics, proteomics, bioinformatics, and other emerging technologies.
Dr. von Eschenbach entered government service after an outstanding career over three decades as a physician, surgeon, oncologist and executive that included numerous leadership roles from Chairman of the Department of Urologic Oncology to Executive Vice President and Chief Academic at the University of Texas M.D. Anderson Cancer Center in Houston, an institution world renowned for the magnitude and excellence of its clinical and research cancer programs. An internationally renowned cancer specialist and author of more than 200 scientific articles and studies, Dr. von Eschenbach has served in numerous leadership roles, including serving as one of the founding members of the National Dialogue on Cancer. He has received numerous professional awards and honors. In 2006, Dr. von Eschenbach was named one of Time magazine’s “100 most influential people to shape the world”, and in both 2007 and 2008, he was selected as one of the Modern Healthcare/Modern Physician’s “50 Most Powerful Physician Executives in Healthcare”.
Dr. von Eschenbach earned a B.S. from St. Joseph’s University in his native Philadelphia and his medical degree from Georgetown University School of Medicine in Washington, D.C. He served as a Lt. Commander in the U.S. Navy Medical Corps. After completing a residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he was an instructor in urology at the University of Pennsylvania School of Medicine. He completed a Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center.
Dr. Chad Mirkin has been recognized for his accomplishments with over 50 national and international Awards. These include a iCON Innovator of the Year Award (2007), NIH Director’s Pioneer Award, the Collegiate Inventors Award (2002, 2004), an Honorary Doctorate Degree from Dickinson College, the Pennsylvania State University Outstanding Science Alumni Award, the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, a Dickinson College Metzger-Conway Fellowship, the 2003 Raymond and Beverly Sackler Prize in the Physical Sciences, the Feynman Prize in Nanotechnology, the Leo Hendrick Baekeland Award, Crain’s Chicago Business “40 under 40 Award,” the Discover 2000 Award for Technological Innovation, I-Street Magazine’s Top 5 List for Leading Academics in Technology, the Materials Research Society Young Investigator Award, the ACS Award in Pure Chemistry, the PLU Fresenius Award, the Harvard University E. Bright Wilson Prize, the BF Goodrich Collegiate Inventors Award, the Camille Dreyfus Teacher-Scholar Award, the Alfred P. Sloan Foundation Award, the DuPont Young Professor Award, the NSF Young Investigator Award, the Naval Young Investigator Award, the Beckman Young Investigator Award, and the Dreyfus Foundation New Faculty Award.
He is a Fellow of the American Association for the Advancement of Science and has served on the Editorial Advisory Boards of over twenty scholarly journals. At present he is a member of the Editorial Advisory Boards of Accounts of Chemical Research, Advanced Materials, Angewandte Chemie, BioMacromolecules, Macromolecular Bioscience, SENSORS, Encyclopedia of Nanoscience and Nanotechnology, Chemistry-A European Journal, Chemistry & Biology, Nanotechnology Law & Business, The Scientist, Journal of Materials Chemistry, and Journal of Cluster Science, Plasmonics. Dr. Mirkin is the founding editor of the journal Small, one of the premier international nanotechnology journals, and he has co–edited two bestselling books on the field of nanobiotechnology.
Dr. Mirkin holds a B.S. degree from Dickinson College (1986, elected into Phi Beta Kappa) and a Ph.D. degree in chemistry from the Pennsylvania State University (1989). He was an NSF Postdoctoral Fellow at the Massachusetts Institute of Technology prior to becoming a chemistry professor at Northwestern University in 1991.
Thomas A. Tombrello, Ph.D. is the Chairman of the Division of Physics, Mathematics, and Astronomy at the California Institute of Technology and is the William R. Kenan, Jr. Professor of Physics. He has served as Caltech's Technology Assessment Officer since 1996. In this role, Dr. Tombrello is responsible for identifying and evaluating new and promising technologies for the Institute. From 1987 to 1989, Dr. Tombrello was Vice President and Director of Research at Schlumberger-Doll Research.
Among his many honors, Dr. Tombrello is a fellow of the American Physical Society. His research has primarily focused on applications of nuclear and ion beam physics to problems in materials science, geochemistry, and technology. Dr. Tombrello earned his B.A., M.A. and Ph.D. degrees in Physics at Rice University in Houston.
About Nanotechnology
Nanotechnology is the investigation and design of materials and devices at the atomic and molecular levels. The engineering of materials and devices at the nanoscale is expected to unleash fundamental paradigm shifts in a range of different industries. Large multinational corporations are investing heavily in commercialization efforts and the federal government has authorized an aggregate of $3.7 billion for nanoscale science and engineering projects between 2005 and 2008. Already, nanomaterials are being used to make stain resistant and wrinkle free clothing, lighter and stronger baseball bats, and more durable epoxies and paints. Although nanotechnology is likely to impact virtually every industry ranging from textiles to aerospace, we believe that the most far-reaching impacts of nanoscience will be in medicine, electronics, and energy.
Nanotechnology is contributing to medical advances such as applications in drug development and delivery, diagnostics, stem cell therapeutics, and personalized medicine. Recent breakthroughs in life sciences such as the sequencing of the human genome, the discovery of RNA interference (RNAi), and advances in stem cell techniques are enabling new understanding of diseases and approaches to treatments. Nanotechnology involves engineering on a molecular level; biological processes happen at the molecular scale. Nanotechnology combines the traditional disciplines of chemistry, materials science, physics and biology and enables the manipulation of matter in powerful new ways. Using the knowledge from all of these disciplines, medicines and diagnostic agents can be designed to interact with cells and tissues with a high degree of specificity and functionality.
The electronics industry is leveraging nanomaterials in devices that are faster, cheaper, more flexible, and consume less energy. Electronic materials and devices used over the past several decades have reached their performance limits. Additionally, because traditional electronic materials such as indium tin oxide, copper, aluminum, and silicon are mined, they are finite and subject to supply shortages. Nanomaterials are being used to enhance the performance of traditional electronic products and to address technological challenges encountered by existing electronics manufacturers.
In energy, nanotechnology is enabling the manufacture of new kinds of solar cells, fuel cells, batteries, and super capacitors. Existing solar cells based on crystalline silicon are bulky and expensive. If successfully developed, solar cells incorporating nanomaterials could be cheaper, lighter and more flexible. Similarly, nanomaterials could yield new light, emitting diodes that are brighter and consume less power than existing sources of lighting. Nanostructured materials promise to give rise to new batteries that last longer, have more energy, and are a fraction of the size of conventional batteries.
Portfolio Companies
Arrowhead Research Corporation forms or acquires companies pursuing product and technology development in nanotechnology. Arrowhead's strategy is to maintain or build a majority interest in its portfolio companies. We provide financial, administrative, corporate and strategic resources. This structure is designed to enable each management and technical team at the portfolio level to focus on developing specific technologies for specific markets.
Arrowhead currently has two majority-owned subsidiaries, Unidym and Calando, and has minority investments in two early-stage nanotechnology companies, Nanotope, Inc. and Leonardo Biosystems, Inc.
Unidym is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners.
Calando Pharmaceuticals, Inc. employs its proprietary nanotechnology exclusively on therapeutic use of RNAi (RNA interference), a technique to “silence” the expression of genes that cause diseases. Calando’s self-assembling nanoparticles, comprised of Calando’s proprietary polymer delivery system and in RNAi therapeutic, are designed for intravenous injection and have shown exemplary results in small-scale animal studies.
Nanotope is a regenerative medicine company developing a highly flexible and customizable platform out of Northwestern University. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope is positioned to enter into a commercialization corporate partnership in 2010 and expects to be able to start a first round of clinical trials in 2010.
Leonardo Biosystems has a multi-stage delivery platform that has been shown in animal models to be highly effective in targeting delivery of siRNA and small molecule drugs. It expects to enter into commercial development partnerships in 2010.
Sponsored Research
Arrowhead invests in nanoscience research and development at universities. In return for financing, Arrowhead obtains rights to exclusively license and commercialize technologies generated through the research.
In each case, the researchers focus their efforts on achieving mutually agreed upon goals and Arrowhead monitors progress and works with the researchers in patenting inventions.
We identify and fund research programs that have the potential to result in the formation of a new majority-owned subsidiary, support the work of one or more of our current subsidiaries, or add to our intellectual property portfolio. We have engaged in collaborations with Caltech, Duke, Stanford, and the University of Florida in the areas of molecular diagnostics, stem cell research, and carbon-based electronics. We are currently evaluating new opportunities and will partner with additional nanotechnology researchers.
Arrowhead Press Releases
http://www.arrowheadresearch.com/news.html
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=arwr
Jun 4, 2010 Unidym and Tokyo Electron Begin Joint Program to Develop Large Scale Manufacturing Equipment for Printable Carbon Nanotube-Based Displays and Solar Cells
Jun 4, 2010 www.EquityTradingAlert.com: Stock Alerts For June 4, 2010 Are June 2, 2010 - International Building Technologies Group, Inc. (OTCBB: INBG), June 1, 2010 - Banneker, Inc. (PINKSHEETS: BANI), June 1, 2010 - Angel Acquisition Corp (OTCBB: AGEL), June 1, 2010 - Arrowhead Research Corporation...
Jun 1, 2010 Arrowhead Research Announces Clinical Data Presentations at the 2010 ASCO Annual Meeting on June 6, 2010
May 28, 2010 Arrowhead to Present at Noble Financial Sixth Annual Equity Conference
May 27, 2010 Arrowhead Lead Scientific Advisor, Dr. Mauro Ferrari and Calando Pharmaceuticals' siRNA Drug Delivery Platform Featured in Houston Chronicle
May 19, 2010 Unidym and Guardian Industries Form Partnership to Develop and Commercialize Carbon Coated Glass Products
May 13, 2010 Arrowhead Reports Fiscal 2010 Second Quarter Financial Results
May 7, 2010 www.StockMarketingInc.com: Welcome To Stock Marketing Inc. Check Us Out!! Strong Alerts!! IWEB,HALO,USAT,CNQR,ACTU,ARWR
May 7, 2010 Arrowhead Research to Report Second Quarter Fiscal 2010 Financial Results and Host Conference Call on Thursday, May 13, 2010
Apr 26, 2010 Arrowhead Announces the Appointment of Former FDA Commissioner and National Cancer Institute Director Dr. Andrew von Eschenbach to Its Board of Advisors
From the CEO Link
http://www.arrowheadresearch.com/fromceo.html
Contact Investor Relations
Brandi Floberg
The Piacente Group
(212) 481-2050
Email: ir@arrowres.com
ARROWHEAD RESEARCH CORPORATION is a publicly-owned corporation trading on NASDAQ under the ticker symbol ARWR.
http://www.arrowheadresearch.com/relations.html
About Unidym Research
COMPANY OVERVIEW
Unidym, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), is a leader in the manufacture and application of carbon nanotube (CNT) based ink and conductive film products and CNTs, a novel material with extraordinary electrical, mechanical, chemical, and thermal properties. Unidym provides CNT-enabled products, specialized CNT materials, and intellectual property to a wide range of customers and business partners.
Building directly on the work of the late Dr. Richard Smalley, the Nobel Prize winning pioneer of carbon nanotubes, and Distinguished Professor George Grüner at UCLA, Unidym has created one of the most experienced teams in CNT science and the most expansive intellectual property portfolio in the CNT industry. With the addition of the experience and strengths of Carbon Nanotechnologies (CNI), Unidym’s current patent portfolio contains more than 200 foreign and domestic patents and patent applications, including more than 90 issued patents. The portfolio includes fundamental patents covering carbon nanotube compositions, production (synthesis, purification and dispersion) and use in many different application areas, including electronics, composite materials, energy storage/generation, medical devices and drug delivery.
Unidym is focused on the electronics industry where its initial product is a transparent electrode for touch screens, flat panel displays, solar cells, and solid state lighting. Unidym is developing thin film transistors for printable electronics and the emerging flexible display market. Additionally, Unidym has developed a range of proprietary CNTs for conductive polymers, structural reinforcement materials, and anti-static films.
Unidym's product line builds upon the growing trend in the electronics industry to replace today's high-cost materials and manufacturing processes with simpler, lower-cost production techniques similar to those found in the printing industry. Termed flexible or printable electronics, this opportunity is forecast by independent experts at IDTechEx to grow to $30 billion by 2015 and to as much as $250 billion by 2025.
Unidym is also pursuing an aggressive, cross-industry partnership strategy to foster the commercialization of CNTs in a broad range of applications. Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications. With its licensing program, technical expertise and manufacturing facilities, Unidym is uniquely equipped to enable partners to rapidly develop CNT solutions for their specific applications.
Unidym is headquartered in Sunnyvale, California.
http://www.unidym.com/index.html
PRODUCT OVERVIEW
Unidym offers or has under development a range of products that exploit the extraordinary properties of carbon nanotubes. While Unidym's current sales and development efforts are focused on applications in electronics, the company also provides products for the life sciences, automotive, and energy industries.
Specialty Carbon Nanotube Materials
Unidym produces specialized grades of carbon nanotubes in close collaboration with customers and partners. Unidym can tailor the properties of the carbon nanotubes to meet customers' specific needs. Unidym's carbon nanotubes offer conductivity, mechanical stability, and superior environmental resistance in numerous applications.
Transparent Conductive Films
Unidym has developed CNT-based transparent inks that can be applied to substrates to create Transparent Conductive Films (TCF). These films will replace brittle and expensive indium tin oxide (ITO) films currently used in touch screens, LCD displays, solar cells, and solid state (OLED) lighting.
Solar
Unidym's transparent conductive films and innovative CNT materials offer compelling cost and performance benefits to next generation solar cells.
Vertical Aligned Nanotube Array
Thermal Interface Management
http://www.unidym.com/products/index.html
Specialty Carbon Nanotube Materials
Unidym produces specialized grades of carbon nanotubes in close collaboration with customers and partners. Unidym can tailor the properties of the carbon nanotubes to meet customers' specific needs. Unidym's carbon nanotubes offer conductivity, mechanical stability, and superior environmental resistance in numerous applications.
Transparent Conductive Films
Unidym has developed CNT-based transparent inks that can be applied to substrates to create Transparent Conductive Films (TCF). These films will replace brittle and expensive indium tin oxide (ITO) films currently used in touch screens, LCD displays, solar cells, and solid state (OLED) lighting.
Solar
Unidym's transparent conductive films and innovative CNT materials offer compelling cost and performance benefits to next generation solar cells.
Vertical Aligned Nanotube Array
Thermal Interface Management
About Calando Pharmaceuticals Research
Company Overview
Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics. We develop nanoparticle therapeutics that use our patented sugar (cyclodextrin)-based polymer technologies as a drug delivery system for siRNA.
Our products are based on pioneering technology invented in the Chemical Engineering Department of the California Institute of Technology. Engineered to reduce the debilitating effects of cancer treatment, our proprietary molecules are designed to improve the safety and efficacy of cancer therapeutics using siRNA as the active ingredient. The target-agnostic platform technology has the potential to be applied to a wide range of diseases beyond cancer as well as to therapeutic classes beyond siRNA therapeutics.
In 2009, we successfully completed a Phase 1 clinical study with our first anti-cancer drug and therapeutic candidate, IT-101. IT-101, along with Calando's drug delivery platform, Cyclosert™, now is partnered for further development to Cerulean Pharma Inc.
http://www.calandopharma.com/about-calando/
RONDEL™ for siRNA Delivery
Years of research leading to clinical breakthroughs.
We are creating and developing new targeted, siRNA-containing therapeutics using our proprietary three part RNAi/Oligonucleotide Nanoparticle Delivery (RONDEL) technology, the foundation of which is our cyclodextrin-containing polymer.
One of the key challenges to using RNAi therapy has been the inability to systemically deliver siRNA in humans. "Naked" siRNA is degraded and destroyed by nucleases in the bloodstream and is not taken up by cells. It also causes harmful immune reactions.
With our RONDEL system, siRNA is protected by our cyclodextrin-containing polymers and thus can reach its destination and perform its intended job, for example, to stop the runaway growth of tumor cells. By encapsulating the siRNA, RONDEL also protects the body from the immune reactions caused by naked siRNA.
Pending successful clinical testing, RONDEL provides an enabling technology for siRNA-based therapeutics to become effective disease treatments.
About Nanotope Research
Nanotope is a regenerative medicine company that leverages a core set of proprietary technologies to address multiple therapeutic markets. This highly flexible and customizable platform was first developed at Northwestern University by Dr. Samuel I. Stupp, Professor of Materials Science & Engineering, Chemistry and Medicine and Director of the Institute for BioNanotechnology in Medicine (IBNAM). Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope?s lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for advanced wound healing and the treatment of peripheral artery disease.
http://www.nanotope.com/index.php
About Leonardo Research
Leonardo Biosystems is a drug delivery company built around technology developed by Dr. Mauro Ferrari, one of the world's best-known nano-cancer scientists. Leonardo has a multi-stage delivery platform that has been shown in animal models to be highly effective in targeting delivery of siRNA and small molecule drugs. The company expects to enter into commercial development partnerships in 2010. Leonardo was co-founded by Dr. Chris Anzalone, Arrowhead Research's CEO, prior to his employment by Arrowhead. Dr. Anzalone serves as the CEO of Leonardo.
Arrowhead Research (Nasdaq: ARWR) holds minority interest in Leonardo Biosystems.
Subsidiary Companies: Tego BioSciences
Tego BioSciences has extensive foundational intellectual property relating to fullerene synthesis and modification for therapeutic purposes and key patents that are critical in making fullerenes into useable products.
Tego is seeking to monetize its proprietary compounds and enabling patents through a licensing and partnership model with a primary focus on establishing partnerships in the areas of MRI contrast agents and treatment of neurodegenerative conditions.
Tego is a wholly owned subsidiary of Arrowhead Research (Nasdaq: ARWR).
Corporate Information
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=arwr
Arrowhead Research Corp.
201 South Lake Avenue
Suite 703
Pasadena, CA 91101
Phone: (626) 304-3400
Primary SIC — Industry Classification
8731 - Commercial physical research
State Of Incorporation
DE
Jurisdiction Of Incorporation
United States
Reporting Standard
U.S. Registered & Reporting: SEC Filer
CIK
0000879407
Fiscal Year End
9/30
Estimated Market Cap
$72,069,290 as of Jun 4, 2010
Outstanding Shares
38,956,373 as of Aug 7, 2008
Number of Shareholders of Record
567 as of Dec 14, 2007
Current Capital Change
shs decreased by 1 for 65 split
Pay Date: Jan 15, 2004
Company Notes
Note=9-30-03 company is in the development stage
Formerly=InterActive Group, Inc. until 1-04
Formerly=InterActive, Inc. until 4-01
Security Notes
New Issue=6-93 1,000,000 shs in units (1 sh Com & 1 Warr 6-16-96) at $4.50 by Paradise Valley Securities, Inc.
Transfer Agent
Computershare Trust Company Inc.
350 Indiana St.
Golden, CO 80401
Finacials and SEC link
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=arwr
Arrowhead Research Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Statements of Operations
(unaudited)
Three Months Ended
3/31/2010 Three Months Ended
3/31/2009 Six Months Ended
3/31/2010 Six Months Ended
3/31/2009 May 7, 2003
(Inception) to
March 31,
2010
REVENUE
$ 157,346 $ 235,650 $ 305,414 $ 937,373 $ 7,813,053
OPERATING EXPENSES
Salaries
1,045,121 2,434,489 2,149,224 5,561,154 42,183,762
Consulting
78,020 343,994 179,259 932,750 8,011,416
General and administrative expenses
733,713 1,026,353 1,479,963 2,611,105 24,544,790
Research and development
351,045 1,506,548 628,833 5,394,853 54,248,991
Patent amortization
78,906 118,556 157,812 208,086 1,944,278
TOTAL OPERATING EXPENSES
2,286,805 5,429,940 4,595,091 14,707,948 130,933,237
OPERATING LOSS
(2,129,459 ) (5,194,290 ) (4,289,677 ) (13,770,575 ) (123,120,184 )
OTHER INCOME (EXPENSE)
Loss on equity of investments—Nanotope
(50,599 ) (60,032 ) (99,238 ) (129,412 ) (439,771 )
Gain on sale of stock in subsidiary
— — — — 2,292,800
Gain on sale of equity of investments—Ensysce
— — — 700,000 700,000
Gain/(loss) on sale of fixed assets, net
50,000 52,457 50,000 52,457 (27,374 )
Realized and unrealized gain in marketable securities
— — — — 382,264
Interest income (expense), net
(14,777 ) (65,382 ) (36,802 ) (56,513 ) 2,773,153
Other income
1,675 — 1,895 — 179,785
TOTAL OTHER INCOME (EXPENSE)
(13,701 ) (72,957 ) (84,145 ) 566,532 5,860,857
LOSS FROM CONTINUING OPERATIONS
(2,143,160 ) (5,267,247 ) (4,373,822 ) (13,204,043 ) (117,259,327 )
Gain/(loss) from discontinued operations
563 (22,032 ) (15,204 ) (115,764 ) (7,581,671 )
Gain/(loss) on disposal of discontinued operations
— — 430,000 — 789,375
INCOME (LOSS) FROM DISCONTINUED OPERATIONS
563 (22,032 ) 414,796 (115,764 ) (6,792,296 )
Provision for income taxes
— — — — —
NET LOSS
(2,142,597 ) (5,289,279 ) (3,959,026 ) (13,319,807 ) (124,051,623 )
Less: Net loss attributable to noncontrolling interests
288,637 — 560,139 60 15,847,877
NET LOSS ATTRIBUTABLE TO ARROWHEAD
$ (1,853,960 ) $ (5,289,279 ) $ (3,398,887 ) $ (13,319,747 ) $ (108,203,746 )
Earnings per share—basic and diluted:
Income (loss) from continuing operations attributable to Arrowhead common shareholders
$ (0.03 ) $ (0.12 ) $ (0.07 ) $ (0.31 )
Income (loss) from discontinued operations attributable to Arrowhead common shareholders
— — 0.01 —
Net income (loss) attributable to Arrowhead shareholders
$ (0.03 ) $ (0.12 ) $ (0.06 ) $ (0.31 )
Weighted average shares outstanding—basic and diluted
62,922,539 42,934,517 60,774,007 42,934,517
The accompanying notes are an integral part of these consolidated financial statements.
Arrowhead Research Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Balance Sheets
(unaudited)
March 31, 2010 September 30,
2009
ASSETS
CURRENT ASSETS
Cash and cash equivalents
$ 2,593,044 $ 2,020,224
Trade receivable, net of allowance for doubtful accounts of $90,789 at March 31, 2010 and $30,789 at September 30, 2009
55,937 144,148
Other receivables
116,382 3,109
Prepaid expenses
225,107 316,074
TOTAL CURRENT ASSETS
2,990,470 2,483,555
PROPERTY AND EQUIPMENT
Computers, office equipment and furniture
374,991 374,991
Research equipment
932,683 932,683
Software
150,445 150,445
Leasehold improvements
94,317 94,317
1,552,436 1,552,436
Less: Accumulated depreciation and amortization
(1,214,306 ) (1,025,392 )
NET PROPERTY AND EQUIPMENT
338,130 527,044
OTHER ASSETS
Rent deposit
104,725 109,648
Patents
2,204,648 2,362,460
Investment in Nanotope Inc., equity basis
1,933,230 2,032,467
Investment in Leonardo Biosystems Inc., at cost
187,000 187,000
TOTAL OTHER ASSETS
4,429,603 4,691,575
TOTAL ASSETS
$ 7,758,203 $ 7,702,174
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable
$ 884,018 $ 1,013,281
Accrued expenses
407,161 420,077
Accrued payroll and benefits
168,536 160,846
Accrued severance
23,500 23,500
Capital lease obligation
296,419 726,534
Note payable
500,000 —
TOTAL CURRENT LIABILITIES
2,279,634 2,344,238
LONG-TERM LIABILITIES
Note payable
— 500,000
TOTAL LONG-TERM LIABILITIES
— 500,000
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Arrowhead Research Corporation shareholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
— —
Common stock, $0.001 par value; 145,000,000 shares authorized; 63,913,753 and 56,411,774 shares issued and outstanding as of March 31, 2010 and September 30, 2009, respectively
63,929 56,428
Additional paid-in capital
114,181,556 110,070,327
Subscription receivable
— (300,000 )
Accumulated deficit during the development stage
(108,367,706 ) (104,968,819 )
Total Arrowhead Research Corporation stockholders’ equity
5,877,779 4,857,936
Noncontrolling interest
(399,210 ) —
TOTAL STOCKHOLDERS’ EQUITY
5,478,569 4,857,936
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$ 7,758,203 $ 7,702,174
The accompanying notes are an integral part of these consolidated financial statements.
Charting and Bar Charts Projections
http://stockcharts.com/h-sc/ui
http://www.insidestocks.com/texpert.asp?sym=ARWR
Overview
Arrowhead Research Corporation is a holding company that forms, acquires, and operates portfolio companies commercializing innovative nanotechnologies. By working closely with leading scientists and universities, Arrowhead identifies the latest advances in nanotechnology and matches them with product development opportunities in high-growth markets. The Company is currently focused on the electronics and biotech industries.
Providing strategic management, financing, and operational services to its portfolio companies, Arrowhead takes an active role in their development, keeping the business and technical development teams at the portfolio level focused on near term revenue opportunities and capital efficiency.
Arrowhead’s strategy is to maintain or build a majority ownserhip position in each portfolio company, thus providing significant exposure to their growth. Arrowhead’s ultimate goal is to monetize the value of its subsidiaries through an initial public offering of subsidiary stock or a sale of a subsidiary to another company. Alternatively, Arrowhead could retain ownership of subsidiary to capture its continuing cash flow and income. Arrowhead is currently focused on its two majority-owned subsidiaries, Unidym, Inc. and Calando Pharmaceuticals, Inc. Arrowhead also owns interests in other development stage nanotechnology companies and is seeking to selectively add to its portfolio.
Download Corporate Profile ( PDF )
http://www.arrowheadresearch.com/corporate_profile_about.html
Management Team
Christopher Anzalone, Ph.D.
President and CEO
Dr. Anzalone is the President and Chief Executive Officer of Arrowhead Research and a majority stockholder of Unidym. He has a wealth of experience in nanotechnology, biotechnology, company-building, and venture capital. Prior to joining Arrowhead, Dr. Anzalone founded and built The Benet Group, a private equity firm focused on creating and building new nanobiotechnology companies from university-generated science. Included in The Benet Group's portfolio are investments in two nanotechnology companies: Nanotope Inc., a tissue regeneration company, and Leonardo Biosystems Inc., a cancer drug delivery company. Prior to Benet, Dr. Anzalone was a partner at the Washington DC-based private equity firm Galway Partners, LLC where he was in charge of sourcing, structuring, and building new business ventures. He was also the founding CEO of NanoInk, Inc., a leading nanolithography company.
Dr. Anzalone holds a Ph.D. and M.A. in Biology from UCLA and a B.A. in Government from Lawrence University.
Board of Directors
Christopher Anzalone, PhD. is the company’s CEO. He is also a member of the company’s board of directors.
R. Bruce Stewart is the founder, director, and Executive Chairman of the Board of Arrowhead Research. A life-long entrepreneur, Mr. Stewart has started and funded over eighteen companies and has taken several of them to the public markets. His capital market experience spans thirty years and he has raised substantial capital for both public and private companies. He is known for his success in building value for shareholders and innovating novel strategies in corporate finance.
Edward W. Frykman has been an Account Executive with Crowell, Weedon & Co. since 1992. Previously, Mr. Frykman served as Senior Vice President of L.H. Friend & Co. Both Crowell, Weedon & Co. and L.H. Friend & Co. are investment brokerage firms located in Southern California. In addition, Mr. Frykman was a Senior Account Executive with Shearson Lehman Hutton where he served as the Manager of the Los Angeles Regional Retail Office of E. F. Hutton & Co.
LeRoy (Lee) T. Rahn was a partner with the intellectual property law firm of Christie, Parker & Hale for more than 30 years, whose practice focused on assisting clients in protecting their intellectual property through obtaining, maintaining and enforcing patents and other legal rights. He is a former president of the Los Angeles Intellectual Property Association and frequently makes presentations on intellectual property law to legal and trade groups. Prior to becoming an attorney, Mr. Rahn obtained a degree in electrical engineering.
Charles P. McKenney has maintained a government affairs law practice in Pasadena, California since 1989, representing businesses and organizations in their relations with government regarding their obligations under state and local land use and trade practices laws. From 1973 through 1989, he served as Attorney for Corporate Government Affairs for Sears, Roebuck and Co., helping organize and carry out Sears' Western state and local government relations programs. Mr. McKenney has served two terms on the Pasadena, California City council, on several city boards and committees in Pasadena, including three city Charter Reform Task Forces.
Scientific Advisory Board
Dr. Mauro Ferrari serves as a Professor & Director, Center for NanoMedicine, Brown Foundation Institute of Molecular Medicine, Chairman, Department of Biomedical Engineering, University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Professor of Bioengineering, Rice University, and President of the Alliance for NanoHealth, Houston TX. Dr. Ferrari received a Ph.D. in Mechanical Engineering from U.C. Berkeley. Dr. Ferrari is a founder of biomedical nano/micro-technology in biomedical applications with more than 160 peer-reviewed journal articles, six books, more than 20 issued patents and about thirty more pending in the US and internationally. His career research and development portfolio totals over $50 million. Dr. Ferrari served as Special Expert on Nanotechnology at the National Cancer Institute in 2003-2005, providing leadership into the establishment of the NCI's Alliance for Nanotechnology.
Dr. Lee Hartwell is a well-known expert in cancer biology and was awarded the Nobel Prize in Medicine in 2001 for his ground-breaking work in cell cycle regulation. Dr. Hartwell is President of the Fred Hutchinson Cancer Research Center in Seattle, Washington. His insights into cell cycle control are being used at the Hutchinson Center and elsewhere to develop treatments for cancer and other diseases. Dr. Hartwell is involved in national and international projects to increase the number of laboratories working in protein diagnostics, develop more team science, improve the availability of informatics for data sharing, provide standardized reagents and stimulate new technology development. Dr. Hartwell is the recipient of many national and international scientific awards. His honors include the Albert Lasker Basic Medical Research Award, the Gairdner Foundation International Award and the Alfred P. Sloan Award in cancer research. He is a member of the National Academy of Sciences. He earned his B.S. at the California Institute of Technology and his Ph.D. from the Massachusetts Institute of Technology. He joined the University of Washington faculty in 1968 and has been a genetics professor there since 1973. In 1996, he joined the faculty of Seattle's Fred Hutchinson Cancer Research Center and, in 1997, became its president and director.
Dr. Andrew von Eschenbach served as Commissioner of the U.S. Food and Drug Administration from 2005 until 2009 where he engaged an agenda to modernize the FDA. Under his leadership, many new programs were designed to strengthen the FDA, including the establishment of a nanotechnology initiative. He emphasized the FDA’s role in working with external partners to assure quality throughout the entire life cycle of the products it regulates while internally fostering, through process improvements, a regulatory pathway that is transparent and efficient while still rigorous and science led. Currently, Dr. von Eschenbach serves as Senior Director for Strategic Initiatives at the Center for Health Transformation, founded by Newt Gingrich, and leads the 21st Century FDA Modernization Project. Dr. von Eschenbach joined the FDA after serving for four years as Director of the National Cancer Institute (NCI) at the National Institutes of Health where he set an ambitious goal to eliminate the suffering and death due to cancer by rapid acceleration and integration of the discovery-development-delivery continuum. While at NCI, he committed resources to ensure the application to oncology of nanotechnology, genomics, proteomics, bioinformatics, and other emerging technologies.
Dr. von Eschenbach entered government service after an outstanding career over three decades as a physician, surgeon, oncologist and executive that included numerous leadership roles from Chairman of the Department of Urologic Oncology to Executive Vice President and Chief Academic at the University of Texas M.D. Anderson Cancer Center in Houston, an institution world renowned for the magnitude and excellence of its clinical and research cancer programs. An internationally renowned cancer specialist and author of more than 200 scientific articles and studies, Dr. von Eschenbach has served in numerous leadership roles, including serving as one of the founding members of the National Dialogue on Cancer. He has received numerous professional awards and honors. In 2006, Dr. von Eschenbach was named one of Time magazine’s “100 most influential people to shape the world”, and in both 2007 and 2008, he was selected as one of the Modern Healthcare/Modern Physician’s “50 Most Powerful Physician Executives in Healthcare”.
Dr. von Eschenbach earned a B.S. from St. Joseph’s University in his native Philadelphia and his medical degree from Georgetown University School of Medicine in Washington, D.C. He served as a Lt. Commander in the U.S. Navy Medical Corps. After completing a residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he was an instructor in urology at the University of Pennsylvania School of Medicine. He completed a Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center.
Dr. Chad Mirkin has been recognized for his accomplishments with over 50 national and international Awards. These include a iCON Innovator of the Year Award (2007), NIH Director’s Pioneer Award, the Collegiate Inventors Award (2002, 2004), an Honorary Doctorate Degree from Dickinson College, the Pennsylvania State University Outstanding Science Alumni Award, the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, a Dickinson College Metzger-Conway Fellowship, the 2003 Raymond and Beverly Sackler Prize in the Physical Sciences, the Feynman Prize in Nanotechnology, the Leo Hendrick Baekeland Award, Crain’s Chicago Business “40 under 40 Award,” the Discover 2000 Award for Technological Innovation, I-Street Magazine’s Top 5 List for Leading Academics in Technology, the Materials Research Society Young Investigator Award, the ACS Award in Pure Chemistry, the PLU Fresenius Award, the Harvard University E. Bright Wilson Prize, the BF Goodrich Collegiate Inventors Award, the Camille Dreyfus Teacher-Scholar Award, the Alfred P. Sloan Foundation Award, the DuPont Young Professor Award, the NSF Young Investigator Award, the Naval Young Investigator Award, the Beckman Young Investigator Award, and the Dreyfus Foundation New Faculty Award.
He is a Fellow of the American Association for the Advancement of Science and has served on the Editorial Advisory Boards of over twenty scholarly journals. At present he is a member of the Editorial Advisory Boards of Accounts of Chemical Research, Advanced Materials, Angewandte Chemie, BioMacromolecules, Macromolecular Bioscience, SENSORS, Encyclopedia of Nanoscience and Nanotechnology, Chemistry-A European Journal, Chemistry & Biology, Nanotechnology Law & Business, The Scientist, Journal of Materials Chemistry, and Journal of Cluster Science, Plasmonics. Dr. Mirkin is the founding editor of the journal Small, one of the premier international nanotechnology journals, and he has co–edited two bestselling books on the field of nanobiotechnology.
Dr. Mirkin holds a B.S. degree from Dickinson College (1986, elected into Phi Beta Kappa) and a Ph.D. degree in chemistry from the Pennsylvania State University (1989). He was an NSF Postdoctoral Fellow at the Massachusetts Institute of Technology prior to becoming a chemistry professor at Northwestern University in 1991.
Thomas A. Tombrello, Ph.D. is the Chairman of the Division of Physics, Mathematics, and Astronomy at the California Institute of Technology and is the William R. Kenan, Jr. Professor of Physics. He has served as Caltech's Technology Assessment Officer since 1996. In this role, Dr. Tombrello is responsible for identifying and evaluating new and promising technologies for the Institute. From 1987 to 1989, Dr. Tombrello was Vice President and Director of Research at Schlumberger-Doll Research.
Among his many honors, Dr. Tombrello is a fellow of the American Physical Society. His research has primarily focused on applications of nuclear and ion beam physics to problems in materials science, geochemistry, and technology. Dr. Tombrello earned his B.A., M.A. and Ph.D. degrees in Physics at Rice University in Houston.
About Nanotechnology
Nanotechnology is the investigation and design of materials and devices at the atomic and molecular levels. The engineering of materials and devices at the nanoscale is expected to unleash fundamental paradigm shifts in a range of different industries. Large multinational corporations are investing heavily in commercialization efforts and the federal government has authorized an aggregate of $3.7 billion for nanoscale science and engineering projects between 2005 and 2008. Already, nanomaterials are being used to make stain resistant and wrinkle free clothing, lighter and stronger baseball bats, and more durable epoxies and paints. Although nanotechnology is likely to impact virtually every industry ranging from textiles to aerospace, we believe that the most far-reaching impacts of nanoscience will be in medicine, electronics, and energy.
Nanotechnology is contributing to medical advances such as applications in drug development and delivery, diagnostics, stem cell therapeutics, and personalized medicine. Recent breakthroughs in life sciences such as the sequencing of the human genome, the discovery of RNA interference (RNAi), and advances in stem cell techniques are enabling new understanding of diseases and approaches to treatments. Nanotechnology involves engineering on a molecular level; biological processes happen at the molecular scale. Nanotechnology combines the traditional disciplines of chemistry, materials science, physics and biology and enables the manipulation of matter in powerful new ways. Using the knowledge from all of these disciplines, medicines and diagnostic agents can be designed to interact with cells and tissues with a high degree of specificity and functionality.
The electronics industry is leveraging nanomaterials in devices that are faster, cheaper, more flexible, and consume less energy. Electronic materials and devices used over the past several decades have reached their performance limits. Additionally, because traditional electronic materials such as indium tin oxide, copper, aluminum, and silicon are mined, they are finite and subject to supply shortages. Nanomaterials are being used to enhance the performance of traditional electronic products and to address technological challenges encountered by existing electronics manufacturers.
In energy, nanotechnology is enabling the manufacture of new kinds of solar cells, fuel cells, batteries, and super capacitors. Existing solar cells based on crystalline silicon are bulky and expensive. If successfully developed, solar cells incorporating nanomaterials could be cheaper, lighter and more flexible. Similarly, nanomaterials could yield new light, emitting diodes that are brighter and consume less power than existing sources of lighting. Nanostructured materials promise to give rise to new batteries that last longer, have more energy, and are a fraction of the size of conventional batteries.
Portfolio Companies
Arrowhead Research Corporation forms or acquires companies pursuing product and technology development in nanotechnology. Arrowhead's strategy is to maintain or build a majority interest in its portfolio companies. We provide financial, administrative, corporate and strategic resources. This structure is designed to enable each management and technical team at the portfolio level to focus on developing specific technologies for specific markets.
Arrowhead currently has two majority-owned subsidiaries, Unidym and Calando, and has minority investments in two early-stage nanotechnology companies, Nanotope, Inc. and Leonardo Biosystems, Inc.
Unidym is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners.
Calando Pharmaceuticals, Inc. employs its proprietary nanotechnology exclusively on therapeutic use of RNAi (RNA interference), a technique to “silence” the expression of genes that cause diseases. Calando’s self-assembling nanoparticles, comprised of Calando’s proprietary polymer delivery system and in RNAi therapeutic, are designed for intravenous injection and have shown exemplary results in small-scale animal studies.
Nanotope is a regenerative medicine company developing a highly flexible and customizable platform out of Northwestern University. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope is positioned to enter into a commercialization corporate partnership in 2010 and expects to be able to start a first round of clinical trials in 2010.
Leonardo Biosystems has a multi-stage delivery platform that has been shown in animal models to be highly effective in targeting delivery of siRNA and small molecule drugs. It expects to enter into commercial development partnerships in 2010.
Sponsored Research
Arrowhead invests in nanoscience research and development at universities. In return for financing, Arrowhead obtains rights to exclusively license and commercialize technologies generated through the research.
In each case, the researchers focus their efforts on achieving mutually agreed upon goals and Arrowhead monitors progress and works with the researchers in patenting inventions.
We identify and fund research programs that have the potential to result in the formation of a new majority-owned subsidiary, support the work of one or more of our current subsidiaries, or add to our intellectual property portfolio. We have engaged in collaborations with Caltech, Duke, Stanford, and the University of Florida in the areas of molecular diagnostics, stem cell research, and carbon-based electronics. We are currently evaluating new opportunities and will partner with additional nanotechnology researchers.
Arrowhead Press Releases
http://www.arrowheadresearch.com/news.html
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=arwr
Jun 4, 2010 Unidym and Tokyo Electron Begin Joint Program to Develop Large Scale Manufacturing Equipment for Printable Carbon Nanotube-Based Displays and Solar Cells
Jun 4, 2010 www.EquityTradingAlert.com: Stock Alerts For June 4, 2010 Are June 2, 2010 - International Building Technologies Group, Inc. (OTCBB: INBG), June 1, 2010 - Banneker, Inc. (PINKSHEETS: BANI), June 1, 2010 - Angel Acquisition Corp (OTCBB: AGEL), June 1, 2010 - Arrowhead Research Corporation...
Jun 1, 2010 Arrowhead Research Announces Clinical Data Presentations at the 2010 ASCO Annual Meeting on June 6, 2010
May 28, 2010 Arrowhead to Present at Noble Financial Sixth Annual Equity Conference
May 27, 2010 Arrowhead Lead Scientific Advisor, Dr. Mauro Ferrari and Calando Pharmaceuticals' siRNA Drug Delivery Platform Featured in Houston Chronicle
May 19, 2010 Unidym and Guardian Industries Form Partnership to Develop and Commercialize Carbon Coated Glass Products
May 13, 2010 Arrowhead Reports Fiscal 2010 Second Quarter Financial Results
May 7, 2010 www.StockMarketingInc.com: Welcome To Stock Marketing Inc. Check Us Out!! Strong Alerts!! IWEB,HALO,USAT,CNQR,ACTU,ARWR
May 7, 2010 Arrowhead Research to Report Second Quarter Fiscal 2010 Financial Results and Host Conference Call on Thursday, May 13, 2010
Apr 26, 2010 Arrowhead Announces the Appointment of Former FDA Commissioner and National Cancer Institute Director Dr. Andrew von Eschenbach to Its Board of Advisors
From the CEO Link
http://www.arrowheadresearch.com/fromceo.html
Contact Investor Relations
Brandi Floberg
The Piacente Group
(212) 481-2050
Email: ir@arrowres.com
ARROWHEAD RESEARCH CORPORATION is a publicly-owned corporation trading on NASDAQ under the ticker symbol ARWR.
http://www.arrowheadresearch.com/relations.html
About Unidym Research
COMPANY OVERVIEW
Unidym, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), is a leader in the manufacture and application of carbon nanotube (CNT) based ink and conductive film products and CNTs, a novel material with extraordinary electrical, mechanical, chemical, and thermal properties. Unidym provides CNT-enabled products, specialized CNT materials, and intellectual property to a wide range of customers and business partners.
Building directly on the work of the late Dr. Richard Smalley, the Nobel Prize winning pioneer of carbon nanotubes, and Distinguished Professor George Grüner at UCLA, Unidym has created one of the most experienced teams in CNT science and the most expansive intellectual property portfolio in the CNT industry. With the addition of the experience and strengths of Carbon Nanotechnologies (CNI), Unidym’s current patent portfolio contains more than 200 foreign and domestic patents and patent applications, including more than 90 issued patents. The portfolio includes fundamental patents covering carbon nanotube compositions, production (synthesis, purification and dispersion) and use in many different application areas, including electronics, composite materials, energy storage/generation, medical devices and drug delivery.
Unidym is focused on the electronics industry where its initial product is a transparent electrode for touch screens, flat panel displays, solar cells, and solid state lighting. Unidym is developing thin film transistors for printable electronics and the emerging flexible display market. Additionally, Unidym has developed a range of proprietary CNTs for conductive polymers, structural reinforcement materials, and anti-static films.
Unidym's product line builds upon the growing trend in the electronics industry to replace today's high-cost materials and manufacturing processes with simpler, lower-cost production techniques similar to those found in the printing industry. Termed flexible or printable electronics, this opportunity is forecast by independent experts at IDTechEx to grow to $30 billion by 2015 and to as much as $250 billion by 2025.
Unidym is also pursuing an aggressive, cross-industry partnership strategy to foster the commercialization of CNTs in a broad range of applications. Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications. With its licensing program, technical expertise and manufacturing facilities, Unidym is uniquely equipped to enable partners to rapidly develop CNT solutions for their specific applications.
Unidym is headquartered in Sunnyvale, California.
http://www.unidym.com/index.html
PRODUCT OVERVIEW
Unidym offers or has under development a range of products that exploit the extraordinary properties of carbon nanotubes. While Unidym's current sales and development efforts are focused on applications in electronics, the company also provides products for the life sciences, automotive, and energy industries.
Specialty Carbon Nanotube Materials
Unidym produces specialized grades of carbon nanotubes in close collaboration with customers and partners. Unidym can tailor the properties of the carbon nanotubes to meet customers' specific needs. Unidym's carbon nanotubes offer conductivity, mechanical stability, and superior environmental resistance in numerous applications.
Transparent Conductive Films
Unidym has developed CNT-based transparent inks that can be applied to substrates to create Transparent Conductive Films (TCF). These films will replace brittle and expensive indium tin oxide (ITO) films currently used in touch screens, LCD displays, solar cells, and solid state (OLED) lighting.
Solar
Unidym's transparent conductive films and innovative CNT materials offer compelling cost and performance benefits to next generation solar cells.
Vertical Aligned Nanotube Array
Thermal Interface Management
http://www.unidym.com/products/index.html
Specialty Carbon Nanotube Materials
Unidym produces specialized grades of carbon nanotubes in close collaboration with customers and partners. Unidym can tailor the properties of the carbon nanotubes to meet customers' specific needs. Unidym's carbon nanotubes offer conductivity, mechanical stability, and superior environmental resistance in numerous applications.
Transparent Conductive Films
Unidym has developed CNT-based transparent inks that can be applied to substrates to create Transparent Conductive Films (TCF). These films will replace brittle and expensive indium tin oxide (ITO) films currently used in touch screens, LCD displays, solar cells, and solid state (OLED) lighting.
Solar
Unidym's transparent conductive films and innovative CNT materials offer compelling cost and performance benefits to next generation solar cells.
Vertical Aligned Nanotube Array
Thermal Interface Management
About Calando Pharmaceuticals Research
Company Overview
Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics. We develop nanoparticle therapeutics that use our patented sugar (cyclodextrin)-based polymer technologies as a drug delivery system for siRNA.
Our products are based on pioneering technology invented in the Chemical Engineering Department of the California Institute of Technology. Engineered to reduce the debilitating effects of cancer treatment, our proprietary molecules are designed to improve the safety and efficacy of cancer therapeutics using siRNA as the active ingredient. The target-agnostic platform technology has the potential to be applied to a wide range of diseases beyond cancer as well as to therapeutic classes beyond siRNA therapeutics.
In 2009, we successfully completed a Phase 1 clinical study with our first anti-cancer drug and therapeutic candidate, IT-101. IT-101, along with Calando's drug delivery platform, Cyclosert™, now is partnered for further development to Cerulean Pharma Inc.
http://www.calandopharma.com/about-calando/
RONDEL™ for siRNA Delivery
Years of research leading to clinical breakthroughs.
We are creating and developing new targeted, siRNA-containing therapeutics using our proprietary three part RNAi/Oligonucleotide Nanoparticle Delivery (RONDEL) technology, the foundation of which is our cyclodextrin-containing polymer.
One of the key challenges to using RNAi therapy has been the inability to systemically deliver siRNA in humans. "Naked" siRNA is degraded and destroyed by nucleases in the bloodstream and is not taken up by cells. It also causes harmful immune reactions.
With our RONDEL system, siRNA is protected by our cyclodextrin-containing polymers and thus can reach its destination and perform its intended job, for example, to stop the runaway growth of tumor cells. By encapsulating the siRNA, RONDEL also protects the body from the immune reactions caused by naked siRNA.
Pending successful clinical testing, RONDEL provides an enabling technology for siRNA-based therapeutics to become effective disease treatments.
About Nanotope Research
Nanotope is a regenerative medicine company that leverages a core set of proprietary technologies to address multiple therapeutic markets. This highly flexible and customizable platform was first developed at Northwestern University by Dr. Samuel I. Stupp, Professor of Materials Science & Engineering, Chemistry and Medicine and Director of the Institute for BioNanotechnology in Medicine (IBNAM). Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope?s lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for advanced wound healing and the treatment of peripheral artery disease.
http://www.nanotope.com/index.php
About Leonardo Research
Leonardo Biosystems is a drug delivery company built around technology developed by Dr. Mauro Ferrari, one of the world's best-known nano-cancer scientists. Leonardo has a multi-stage delivery platform that has been shown in animal models to be highly effective in targeting delivery of siRNA and small molecule drugs. The company expects to enter into commercial development partnerships in 2010. Leonardo was co-founded by Dr. Chris Anzalone, Arrowhead Research's CEO, prior to his employment by Arrowhead. Dr. Anzalone serves as the CEO of Leonardo.
Arrowhead Research (Nasdaq: ARWR) holds minority interest in Leonardo Biosystems.
Subsidiary Companies: Tego BioSciences
Tego BioSciences has extensive foundational intellectual property relating to fullerene synthesis and modification for therapeutic purposes and key patents that are critical in making fullerenes into useable products.
Tego is seeking to monetize its proprietary compounds and enabling patents through a licensing and partnership model with a primary focus on establishing partnerships in the areas of MRI contrast agents and treatment of neurodegenerative conditions.
Tego is a wholly owned subsidiary of Arrowhead Research (Nasdaq: ARWR).
Corporate Information
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=arwr
Arrowhead Research Corp.
201 South Lake Avenue
Suite 703
Pasadena, CA 91101
Phone: (626) 304-3400
Primary SIC — Industry Classification
8731 - Commercial physical research
State Of Incorporation
DE
Jurisdiction Of Incorporation
United States
Reporting Standard
U.S. Registered & Reporting: SEC Filer
CIK
0000879407
Fiscal Year End
9/30
Estimated Market Cap
$72,069,290 as of Jun 4, 2010
Outstanding Shares
38,956,373 as of Aug 7, 2008
Number of Shareholders of Record
567 as of Dec 14, 2007
Current Capital Change
shs decreased by 1 for 65 split
Pay Date: Jan 15, 2004
Company Notes
Note=9-30-03 company is in the development stage
Formerly=InterActive Group, Inc. until 1-04
Formerly=InterActive, Inc. until 4-01
Security Notes
New Issue=6-93 1,000,000 shs in units (1 sh Com & 1 Warr 6-16-96) at $4.50 by Paradise Valley Securities, Inc.
Transfer Agent
Computershare Trust Company Inc.
350 Indiana St.
Golden, CO 80401
Finacials and SEC link
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=arwr
Arrowhead Research Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Statements of Operations
(unaudited)
Three Months Ended
3/31/2010 Three Months Ended
3/31/2009 Six Months Ended
3/31/2010 Six Months Ended
3/31/2009 May 7, 2003
(Inception) to
March 31,
2010
REVENUE
$ 157,346 $ 235,650 $ 305,414 $ 937,373 $ 7,813,053
OPERATING EXPENSES
Salaries
1,045,121 2,434,489 2,149,224 5,561,154 42,183,762
Consulting
78,020 343,994 179,259 932,750 8,011,416
General and administrative expenses
733,713 1,026,353 1,479,963 2,611,105 24,544,790
Research and development
351,045 1,506,548 628,833 5,394,853 54,248,991
Patent amortization
78,906 118,556 157,812 208,086 1,944,278
TOTAL OPERATING EXPENSES
2,286,805 5,429,940 4,595,091 14,707,948 130,933,237
OPERATING LOSS
(2,129,459 ) (5,194,290 ) (4,289,677 ) (13,770,575 ) (123,120,184 )
OTHER INCOME (EXPENSE)
Loss on equity of investments—Nanotope
(50,599 ) (60,032 ) (99,238 ) (129,412 ) (439,771 )
Gain on sale of stock in subsidiary
— — — — 2,292,800
Gain on sale of equity of investments—Ensysce
— — — 700,000 700,000
Gain/(loss) on sale of fixed assets, net
50,000 52,457 50,000 52,457 (27,374 )
Realized and unrealized gain in marketable securities
— — — — 382,264
Interest income (expense), net
(14,777 ) (65,382 ) (36,802 ) (56,513 ) 2,773,153
Other income
1,675 — 1,895 — 179,785
TOTAL OTHER INCOME (EXPENSE)
(13,701 ) (72,957 ) (84,145 ) 566,532 5,860,857
LOSS FROM CONTINUING OPERATIONS
(2,143,160 ) (5,267,247 ) (4,373,822 ) (13,204,043 ) (117,259,327 )
Gain/(loss) from discontinued operations
563 (22,032 ) (15,204 ) (115,764 ) (7,581,671 )
Gain/(loss) on disposal of discontinued operations
— — 430,000 — 789,375
INCOME (LOSS) FROM DISCONTINUED OPERATIONS
563 (22,032 ) 414,796 (115,764 ) (6,792,296 )
Provision for income taxes
— — — — —
NET LOSS
(2,142,597 ) (5,289,279 ) (3,959,026 ) (13,319,807 ) (124,051,623 )
Less: Net loss attributable to noncontrolling interests
288,637 — 560,139 60 15,847,877
NET LOSS ATTRIBUTABLE TO ARROWHEAD
$ (1,853,960 ) $ (5,289,279 ) $ (3,398,887 ) $ (13,319,747 ) $ (108,203,746 )
Earnings per share—basic and diluted:
Income (loss) from continuing operations attributable to Arrowhead common shareholders
$ (0.03 ) $ (0.12 ) $ (0.07 ) $ (0.31 )
Income (loss) from discontinued operations attributable to Arrowhead common shareholders
— — 0.01 —
Net income (loss) attributable to Arrowhead shareholders
$ (0.03 ) $ (0.12 ) $ (0.06 ) $ (0.31 )
Weighted average shares outstanding—basic and diluted
62,922,539 42,934,517 60,774,007 42,934,517
The accompanying notes are an integral part of these consolidated financial statements.
Arrowhead Research Corporation and Subsidiaries
(A Development Stage Company)
Consolidated Balance Sheets
(unaudited)
March 31, 2010 September 30,
2009
ASSETS
CURRENT ASSETS
Cash and cash equivalents
$ 2,593,044 $ 2,020,224
Trade receivable, net of allowance for doubtful accounts of $90,789 at March 31, 2010 and $30,789 at September 30, 2009
55,937 144,148
Other receivables
116,382 3,109
Prepaid expenses
225,107 316,074
TOTAL CURRENT ASSETS
2,990,470 2,483,555
PROPERTY AND EQUIPMENT
Computers, office equipment and furniture
374,991 374,991
Research equipment
932,683 932,683
Software
150,445 150,445
Leasehold improvements
94,317 94,317
1,552,436 1,552,436
Less: Accumulated depreciation and amortization
(1,214,306 ) (1,025,392 )
NET PROPERTY AND EQUIPMENT
338,130 527,044
OTHER ASSETS
Rent deposit
104,725 109,648
Patents
2,204,648 2,362,460
Investment in Nanotope Inc., equity basis
1,933,230 2,032,467
Investment in Leonardo Biosystems Inc., at cost
187,000 187,000
TOTAL OTHER ASSETS
4,429,603 4,691,575
TOTAL ASSETS
$ 7,758,203 $ 7,702,174
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable
$ 884,018 $ 1,013,281
Accrued expenses
407,161 420,077
Accrued payroll and benefits
168,536 160,846
Accrued severance
23,500 23,500
Capital lease obligation
296,419 726,534
Note payable
500,000 —
TOTAL CURRENT LIABILITIES
2,279,634 2,344,238
LONG-TERM LIABILITIES
Note payable
— 500,000
TOTAL LONG-TERM LIABILITIES
— 500,000
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Arrowhead Research Corporation shareholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
— —
Common stock, $0.001 par value; 145,000,000 shares authorized; 63,913,753 and 56,411,774 shares issued and outstanding as of March 31, 2010 and September 30, 2009, respectively
63,929 56,428
Additional paid-in capital
114,181,556 110,070,327
Subscription receivable
— (300,000 )
Accumulated deficit during the development stage
(108,367,706 ) (104,968,819 )
Total Arrowhead Research Corporation stockholders’ equity
5,877,779 4,857,936
Noncontrolling interest
(399,210 ) —
TOTAL STOCKHOLDERS’ EQUITY
5,478,569 4,857,936
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$ 7,758,203 $ 7,702,174
The accompanying notes are an integral part of these consolidated financial statements.
Charting and Bar Charts Projections
http://stockcharts.com/h-sc/ui
http://www.insidestocks.com/texpert.asp?sym=ARWR
SIGN UP FOR $THE WAVE (WAVERIDER$) EMAIL
http://investorshub.advfn.com/boards/board.aspx?board_id=16203
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
